Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

755
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
755
Management of Insomnia01:19

Management of Insomnia

749
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
749
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.1K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.1K
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

1.8K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.8K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

776
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
776
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

2.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nanostructure of tooth enamel casts light on dietary shifts as humans evolved.

Nature·2026
Same author

Polyfunctionalized <i>N</i>-Arylsulfonyl Indoles: Identification of (<i>E</i>)-<i>N</i>-Hydroxy-3-{3-[(5-(3-(piperidin-1-yl)propoxy]-1<i>H</i>-indol-1-yl)sulfonyl]phenyl}acrylamide (MTP150) for the Epigenetic-Based Therapy of Parkinson's Disease.

International journal of molecular sciences·2026
Same author

Proteomic characterization of <i>Lysinibacillus</i> reveals early-stage PET biodegradation potential.

Frontiers in microbiology·2026
Same author

Bibliometric analysis of global hodgkin lymphoma research from 2002 to 2022.

Discover oncology·2026
Same author

External immune sentinels in the seawater ecosystem: the specialization of bivalve hemocytes.

Frontiers in immunology·2026
Same author

Type 1 and CD103<sup>+</sup> Type 2 Conventional Dendritic Cells Are Decreased in Active Patients with Ulcerative Colitis but Not with Crohn's Disease.

European journal of immunology·2026

Related Experiment Video

Updated: Mar 10, 2026

Author Spotlight: Establishing a Reliable Distal MCA Occlusion Model in Mice for Stroke Research
07:34

Author Spotlight: Establishing a Reliable Distal MCA Occlusion Model in Mice for Stroke Research

Published on: December 15, 2023

3.5K

Melatonin and Nitrones As Potential Therapeutic Agents for Stroke.

Alejandro Romero1, Eva Ramos1, Paloma Patiño2

  • 1Department of Toxicology and Pharmacology, Faculty of Veterinary Medicine, Complutense University of Madrid Madrid, Spain.

Frontiers in Aging Neuroscience
|December 10, 2016
PubMed
Summary

New stroke therapies focus on melatonin and nitrones, potent antioxidants that act as free radical scavengers. These agents offer a promising alternative to recombinant tissue-type plasminogen activator (r-tPA) due to their wider therapeutic window and fewer side effects.

Keywords:
melatoninneuroprotectionnitronesoxidative stressstroke

More Related Videos

A Preclinical Model to Assess Brain Recovery After Acute Stroke in Rats
10:15

A Preclinical Model to Assess Brain Recovery After Acute Stroke in Rats

Published on: November 6, 2019

8.9K
A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice
06:54

A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice

Published on: June 22, 2022

3.4K

Related Experiment Videos

Last Updated: Mar 10, 2026

Author Spotlight: Establishing a Reliable Distal MCA Occlusion Model in Mice for Stroke Research
07:34

Author Spotlight: Establishing a Reliable Distal MCA Occlusion Model in Mice for Stroke Research

Published on: December 15, 2023

3.5K
A Preclinical Model to Assess Brain Recovery After Acute Stroke in Rats
10:15

A Preclinical Model to Assess Brain Recovery After Acute Stroke in Rats

Published on: November 6, 2019

8.9K
A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice
06:54

A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice

Published on: June 22, 2022

3.4K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Gerontology

Background:

  • Stroke is a prevalent aging-related disease affecting millions globally.
  • Recombinant tissue-type plasminogen activator (r-tPA) is the sole approved stroke treatment.
  • r-tPA exhibits a narrow therapeutic window and adverse secondary effects, necessitating alternative therapies.

Purpose of the Study:

  • To review emerging neuroprotective strategies for stroke treatment.
  • To highlight the potential of melatonin and novel nitrones as therapeutic agents.
  • To present updated findings on the efficacy of these antioxidants.

Main Methods:

  • Literature review of studies on melatonin and nitrone-based neuroprotection.
  • Analysis of antioxidant mechanisms, specifically free radical scavenging.
  • Compilation of recent research findings on these drug candidates.

Main Results:

  • Melatonin and several new nitrones demonstrate significant antioxidant power.
  • These compounds function effectively as free radical traps.
  • Preliminary results suggest potential for improved therapeutic outcomes compared to r-tPA.

Conclusions:

  • Melatonin and nitrones represent promising neuroprotective agents for stroke.
  • Their antioxidant properties offer a potential advantage over current r-tPA therapy.
  • Further research is warranted to explore their clinical application in stroke management.